Wessolly M, Mairinger E, Borchert S, Bankfalvi A, Mach P, Schmid KW, et al. CAF-Associated Paracrine Signaling Worsens Outcome and Potentially Contributes to Chemoresistance in Epithelial Ovarian Cancer. Front Oncol. 2022;12:Article 850847. https://doi.org/10.3389/fonc.2022.850847.

Buamah PK, Skillen AW. Serum CA 125 concentrations in patients with benign ovarian tumours. J Surg Oncol. 1994;56(2):71–4.

Article  CAS  PubMed  Google Scholar 

Buamah P. Benign conditions associated with raised serum CA-125 concentration. J Surg Oncol. 2000;75(4):264–5.

Article  CAS  PubMed  Google Scholar 

Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res. 2008;14(16):5198–208.

Article  CAS  PubMed  Google Scholar 

Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609–15.

Yang Z, Xu S, Jin P, Yang X, Li X, Wan D, et al. MARCKS contributes to stromal cancer-associated fibroblast activation and facilitates ovarian cancer metastasis. Oncotarget. 2016;7(25):37618–30.

Waldron L, Riester M, Birrer M. Molecular subtypes of high-grade serous ovarian cancer: the holy grail? J Natl Cancer Inst. 2014 Sep 30;106(10):dju297. https://doi.org/10.1093/jnci/dju297.

Giusti R, Porzio G, Maltoni M, Filetti M, Cuomo A, Bandieri E, et al. Association of opioid use with survival in patients with cancer treated with immune checkpoint inhibitors: it is time for evidence-based behaviors. Oncologist. 2024;29(1):1–10.

Singh R, Singh S, Grizzle WE, Lillard JW. CXCL13 and CXCR5 expression by non-small cell lung carcinoma. J Immunol. 2011;186(1):149.15.

El Haibi CP, Sharma PK, Singh R, Johnson PR, Suttles J, Singh S, et al. PI3Kp110-, Src-, FAK-dependent and DOCK2-independent migration and invasion of CXCL13-stimulated prostate cancer cells. Mol Cancer. 2010;9:85.

Article  PubMed  PubMed Central  Google Scholar 

Singh R, Stockard CR, Grizzle WE, Lillard JW Jr, Singh S. Expression and histopathological correlation of CCR9 and CCL25 in ovarian cancer. Int J Oncol. 2011;39(2):373–81.

PubMed  Google Scholar 

El-Haibi CP, Singh R, Sharma PK, Singh S, Lillard JW Jr. CXCL13 mediates prostate cancer cell proliferation through JNK signalling and invasion through ERK activation. Cell Prolif. 2011;44(4):311–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bergsten TM, Levy SE, Zink KE, Lusk HJ, Pergande MR, Cologna SM, et al. Fallopian tube secreted protein affects ovarian metabolites in high grade serous ovarian cancer. Front Cell Dev Biol. 2022;10:1042734.

Article  PubMed  PubMed Central  Google Scholar 

Grassi ES, Pietras A. Emerging roles of DLK1 in the Stem cell niche and cancer stemness. J Histochem Cytochem. 2022;70(1):17–28.

Article  CAS  PubMed  Google Scholar 

Pittaway JFH, Lipsos C, Mariniello K, Guasti L. The role of delta-like non-canonical Notch ligand 1 (DLK1) in cancer. Endocr Relat Cancer. 2021;28(12):R271–87.

Article  CAS  PubMed  Google Scholar 

Oldham MC, Konopka G, Iwamoto K, Langfelder P, Kato T, Horvath S, et al. Functional organization of the transcriptome in human brain. Nat Neurosci. 2008;11(11):1271–82.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550.

Article  PubMed  PubMed Central  Google Scholar 

Kassuhn W, et al. Classification of molecular subtypes of high-grade serous ovarian cancer by MALDI-imaging. Cancers (Basel). 2021 Mar 25;13(7):1512. https://doi.org/10.3390/cancers13071512.

Ignatiadis N, Klaus B, Zaugg JB, Huber W. Data-driven hypothesis weighting increases detection power in genome-scale multiple testing. Nat Methods. 2016;13(7):577–80. https://doi.org/10.1038/nmeth.3885.

Zhu A, Ibrahim JG, Love MI. Heavy-tailed prior distributions for sequence count data: removing the noise and preserving large differences. Bioinformatics. 2018;35(12):2084–92.

Article  PubMed Central  Google Scholar 

Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. 2008;9:559.

Article  PubMed  PubMed Central  Google Scholar 

Langfelder P, Horvath S. Fast R functions for robust correlations and hierarchical clustering. J Stat Softw. 2012;46(11):i11. https://doi.org/10.18637/jss.v046.i11.

Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Gene ontology: tool for the unification of biology. Gene Ontology Consortium Nat Genet. 2000;25(1):25–9.

CAS  PubMed  Google Scholar 

Reimand J, Isserlin R, Voisin V, Kucera M, Tannus-Lopes C, Rostamianfar A, et al. Pathway enrichment analysis and visualization of omics data using g:Profiler, GSEA Cytoscape and EnrichmentMap. Nat Protoc. 2019;14(2):482–517.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jiménez-Sánchez A, Cybulska P, Mager KL, Koplev S, Cast O, Couturier D-L, et al. Unraveling tumor–immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy. Nat Genet. 2020;52(6):582–93.

Article  PubMed  PubMed Central  Google Scholar 

Seitz S, Dreyer TF, Stange C, Steiger K, Bräuer R, Scheutz L, et al. CXCL9 inhibits tumour growth and drives anti-PD-L1 therapy in ovarian cancer. Br J Cancer. 2022;126(10):1470–80.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Konecny GE, Wang C, Hamidi H, et al. Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer. J Natl Cancer Inst. 2014;106(10):dju249. https://doi.org/10.1093/jnci/dju249.

Keathley R, Kocherginsky M, Davuluri R, Matei D. Integrated multi-omic analysis reveals immunosuppressive phenotype associated with poor outcomes in high-grade serous ovarian cancer. Cancers. 2023;15(14):3649.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Racle J, Gfeller D. EPIC: a tool to estimate the proportions of different cell types from bulk gene expression data. Methods Mol Biol. 2020;2120:233–48.

Article  CAS  PubMed  Google Scholar 

Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77(21):e108–10.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shapouri-Moghaddam A, Mohammadian S, Vazini H, Taghadosi M, Esmaeili SA, Mardani F, et al. Macrophage plasticity, polarization, and function in health and disease. J Cell Physiol. 2018;233(9):6425–40.

Article  CAS  PubMed  Google Scholar 

Kadomoto S, Izumi K, Mizokami A. Macrophage polarity and disease control. Int J Mol Sci. 2021;23(1):144. https://doi.org/10.3390/ijms23010144.

Zhu S, Yi M, Wu Y, Dong B, Wu K. Roles of tumor-associated macrophages in tumor progression: implications on therapeutic strategies. Exp Hematol Oncol. 2021;10(1):60. https://doi.org/10.1186/s40164-021-00252-z.

Zhu S, Yi M, Wu Y, Dong B, Wu K. Correction to: Roles of tumor-associated macrophages in tumor progression: implications on therapeutic strategies. Exp Hematol Oncol. 2022;11(1):4.

Article  PubMed  PubMed Central  Google Scholar 

Yang Q, Guo N-n, Zhou Y, Chen J, Wei Q, Han M. The role of tumor-associated macrophages (TAMs) in tumor progression and relevant advance in targeted therapy. Acta Pharmaceutica Sinica B. 2020;10:2156–70.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kepuladze S, Devadze R, Gvenetadze A, Burkadze G. Distribution of tumor-associated macrophages and M1/M2 polarization in different types and grades of ovarian tumors. Indian J Pathol Oncol. 2022;9:318–21. https://doi.org/10.18231/j.ijpo.2022.076.

Yin M, Shen J, Yu S, Fei J, Zhu X, Zhao J, et al. Tumor-Associated Macrophages (TAMs): a critical activator in ovarian cancer metastasis. Onco Targets Ther. 2019;12:8687–99.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24(10):1550–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jin J, Wang Y, Ma Q, Wang N, Guo W, Jin B, et al. LAIR-1 activation inhibits inflammatory macrophage phenotype in vitro. Cell Immunol. 2018;331:78–84.

Article  CAS  PubMed  Google Scholar 

Deng Y, Song Z, Huang L, Guo Z, Tong B, Sun M, et al. Tumor purity as a prognosis and immunotherapy relevant feature in cervical cancer. Aging (Albany NY). 2021;13(22):24768–85.

Article  CAS